Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study

Cancer Medicine
Zhanhong ChenYongmei Yin

Abstract

Previous case reports have shown the promising antitumor activity of everolimus in solid tumors containing molecular aberrations in PI3K/ATK/mTOR pathway, however, whether it is effective in patients with breast cancer remains unknown. Therefore, we conducted this retrospective cohort study to compare the efficacy of molecularly matched targeted therapy with everolimus to conventional therapy in refractory breast cancer patients harboring PI3K/ATK/mTOR pathway activating mutations. Refractory metastatic breast cancer patients who have received molecular screening using next-generation sequencing (NGS) between September 8, 2015 and October 30, 2017 in two sites were screened for this study. The primary outcome was progression-free survival (PFS). The secondary outcomes were overall response rate (ORR), disease control rate (DCR), and safety profile. A total of 78 patients were screened for analysis, amongst all, 52 (66.7%) had at least one gene mutation in PI3K/AKT/mTOR pathway. The most common mutation fell in PIK3CA (76.9%, 40/52) with a mutational prevalence of 51.3%. Of the 32 patients who were eligible for efficacy analysis, patients in the everolimus group (n = 19) exhibited shorter PFS than those in the conventional group...Continue Reading

References

May 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Sherene LoiChristos Sotiriou
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffRobert Penny
Jun 5, 2012·Cancer Treatment Reviews·Sara A HurvitzRichard S Finn
Sep 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Apostolia-Maria TsimberidouRazelle Kurzrock
Sep 12, 2014·Cancer·Rafeek A YusufFunda Meric-Bernstam
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N HortobagyiJosé Baselga
Apr 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice AndréDennis Slamon
Nov 30, 2016·Cancer Metastasis Reviews·Angel Guerrero-ZotanoCarlos L Arteaga
Dec 9, 2016·JAMA Oncology·Howard Jack West
Feb 10, 2017·Journal of Hematology & Oncology·Sophie CousinAntoine Italiano
May 28, 2017·Cold Spring Harbor Molecular Case Studies·Christine A ParachoniakJuliann Chmielecki
Nov 1, 2017·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Kazuhiro Araki, Yasuo Miyoshi
Nov 28, 2017·Breast Cancer Research and Treatment·Rossanna C PezoPhilippe L Bedard
Dec 30, 2017·Journal of breast cancer·Zongbi Yi, Fei Ma
Mar 7, 2018·Journal of Experimental & Clinical Cancer Research : CR·Matteo AllegrettiPatrizio Giacomini

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Software Mentioned

GraphPad
R
R Development Core
GraphPad Prism
SPSS

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.